Opinion: How much should psychedelics researchers disclose about their personal use?
Stat News • 2/2/2026
Summary
The article discusses the extent to which psychedelics researchers should disclose their personal use of substances such as psilocybin and ketamine. It raises questions about transparency in the field of psychedelics research.
Advertisement
Lindy Score Breakdown (V4.2)
60d
Age
1
Sources
from cluster
1444
Hours Since Seen
Final Score0/100
CategoryAntiLindy
StatusArchived
Recency Multiplier0% (0.5^1444/48)
Hero EligibleNo
Score is 0 because recency decay (0.5^1444/48 = 0.000000) reduced it below 0.5
Score BreakdownRisk 50
Source Reputation: Low-trust source (4/20 pts)
Consensus: Single source - no independent confirmation yet
Age: 60 days - proven survivor
Stories gain Lindy status through source reputation, network consensus, and time survival.
Breaking Similar stories
Opinion: Medical misinformation wins when patients can’t see their doctors
Stat News • 1 day ago
Opinion: Medical marijuana should not be recommended for PTSD, anxiety, or depression
Stat News • 2 days ago
Opinion: Medicare is restricting care for 1 million Americans based on a faulty assumption. Congress must intervene
Stat News • 2 days ago
Opinion: My patient would rather take a peptide than a statin. That reveals an uncomfortable truth in medicine
Stat News • Today
Opinion: Subscription pricing could expand access to HIV prevention breakthrough while controlling costs
Stat News • Today
Opinion: STAT+: Cardiology’s finally prioritizing prevention — but what will it look like?
Stat News • 1 day ago
Supreme Court rules against conversion therapy ban
Stat News • 2 days ago
CDC stops testing for rabies, pox viruses
Stat News • 1 day ago
STAT+: Trump announces 100% tariffs on brand-name drugs, with plenty of carveouts
Stat News • Today
STAT+: FDA’s evolving view of what makes a ‘breakthrough’ device
Stat News • Today
Anti-Lindy Similar stories
STAT+: Pharmalittle: We’re reading about a Merck acquisition, the rise of former Loxo execs at Lilly, and more
Stat News • 1 week ago
STAT+: Pharmalittle: We’re reading about an FDA OK for a rare disease drug, a grilling of the PTO chief, and more
Stat News • 1 week ago
STAT+: Pharmalittle: We’re reading about Trump pushing drug pricing policy, Chinese biotech licensing, and more
Stat News • 4 days ago
STAT+: FDA approves Denali Therapeutics drug for Hunter syndrome
Stat News • 1 week ago